Advanced searches left 3/3

Sleep Apnea - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 12 September 2022

* If you want to update the article please login/register

Propranolol for Sleep Apnea Therapy

In obstructive sleep apnea patients, free fatty acids and glucose elevations occur during the night, and they may be responsible for adverse cardio-metabolic effects of OSA. In this study, researchers will give patients with OSA before sleep with propranolololol or placebo. In the event of CPAP withdrawal, investigators will examine nocturnal metabolic profiles and hemodynamics on/off propranolololol. The study by "PROSAT 2" investigates whether propranolol reduces changes in blood pressure, heart rate, and blood flow during sleep. There are only two visits on PROSAT 2, both after CPAP withdrawal, and both after CPAP removal.

Source link: https://clinicaltrials.gov/ct2/show/NCT03049306


Sleep Apnea in Patients With MGUS and MM

Obesity is a risk factor for MM growth, although the exact mechanisms linking obesity and MM are uncertain. Interestingly, the key risk factors for both sleep apnea and MM are overlapping. Investigators exposed C57BL/6 mice, who are normally immune to engraftment of malignant plasma cells to CIH, followed by injection of malignant 5TGM1 cells. These mice had key characteristics of the myeloma phenotype, including bone damage and gammopathy, and gammopathy. Investigators investigated potential mechanisms by which CIH promotes MM progression by doing complete bone marrow RNASeq analysis. Investigators also found increased regulation of B cell and plasma cell differentiation pathway formation and differentiation pathway, as well as downregulation of B-cell apoptosis pathways. The progression to MM is based on preliminary results, which combine the overarching conclusion is that CIH raises oxidative stress, therefore promoting B cell maturation and changing the bone marrow stromal microenvironment.

Source link: https://clinicaltrials.gov/ct2/show/NCT04114084


Fitbit Sleep Apnea Alert Software Validation Study

This clinical validation study will determine the effectiveness of Fitbit's Sleep Apnea services for minimallyinvasive monitoring of sleep apnea activity in order to warn consumers of their sleep problems. The Sleep Apnea Alert software is an investigational software as medical device and it is designed to retrospectively process data and identify users who have physiological signs consistent with an apnea index of 15 or greater.

Source link: https://clinicaltrials.gov/ct2/show/NCT03775291


A Validation Study of the NightOwl Home Sleep Apnea Test

The aim of this report is to assess the results of a miniaturized sleep apnea test called NightOwl. The investigators will compare the apnea index estimate, which is the gold standard for sleep apnea diagnosis, to the apnea index calculated as the number of respiratory events per hour of sleep determined by the NightOwl system.

Source link: https://clinicaltrials.gov/ct2/show/NCT04764734


Ansa Cervicalis and Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea

Obstructive Sleep Apnea is a common condition that has resulted in repetitive upper airway damage as a result of particular upper airway muscle tone, as well as multiple related health sequelae affecting millions of Americans. Despite the recent promising development of hypoglossal nerve stimulation as a surgical procedure, its results are limited and a minority of eligible patients do not get a positive response, leaving a significant need for safe therapeutic alternatives to PAP. Our results show that ansa cervicalis stimulation of the sternothyroid muscle relaxes and expands the lateral pharyngeal walls and muscle tensions the distal edge of the soft palate caudally, raising airway patency. The underlying hypothesis of the Investigators is that ACS overcomes specific anatomic and neuromuscular abnormalities of upper airway control that improve pharyngeal patency in patients with OSA.

Source link: https://clinicaltrials.gov/ct2/show/NCT05501236


Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease

Participants with Parkinson's disease and sleep apnea will be able to take levodopa and placebo at bedtime for two weeks each, in a randomized order, with a 2-week washout period in-between.

Source link: https://clinicaltrials.gov/ct2/show/NCT03111485


Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)

The brain can be more vulnerable to OSA side effects and more sensitive to OSA therapy when it is already affected by a degenerative process such as PD. The investigators also discovered an association between OSA and poor cognition in preliminary study in PD patients, as well as cognitive enhancement with PAP therapy. In a randomized controlled trial, the investigators now want to more thoroughly investigate the effects of OSA treatment on cognitive function in PD. The investigators' main aim is to determine the effect of OSA therapy on global cognitive function in PD patients with OSA and cognitive impairment. Patients from the McGill Movement Disorders Clinic and other Quebec Parkinson Network Centres will be recruited from the McGill Movement Disorders Clinic and other Quebec Parkinson Network Centres. At the end of the study period, participants will have polysomnography on their respective therapies to determine success in relation to OSA therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT02209363


Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea

Quetiapine is a drug used to treat schizophrenia and bipolar disorder. Both Insomnia and obstructive sleep apnea are common, but differential diagnosis can be difficult. While quetiapine can improve sleep and breathing in some people, an early review showed that quetiapine caused breathing difficulties in healthy people. Participants with mild-moderate OSA will spend two nights in the sleep lab, one with quetiapine at a dose commonly prescribed for insomnia and one with placebo.

Source link: https://clinicaltrials.gov/ct2/show/NCT05303935


Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

A direct examination of brain oxygen saturation levels that traditional sleep study findings are unable to capture and may be able to better explain health effects related to this condition. The purpose of this survey was to identify a wearable, point-of-care NIRS device that records multiple physiological parameters with a focus on cerebral and peripheral oxygenation in children with obstructive sleep apnea, as well as the relationship between traditional measured results during sleep studies and NIRS technologies. We expect that changes in NIRS signals of cerebral and peripheral tissue oxygenation as a result of apnea events would correlate with respiratory flow and oxygen saturation changes measured with PSG. Primary Goal: Describe cerebral oxygen saturation and peripheral tissue oxygen saturation in children during both normal sleep and sleep apnea conditions with respect to conventional polysomnography norms.

Source link: https://clinicaltrials.gov/ct2/show/NCT05052216


Evaluation of Atomoxetine and Oxybutynin for Obstructive Sleep Apnea in Children With Down Syndrome

This is a prospective, double blind, cross-over research into the use of atomoxetine and oxybutynin in children with DS and OSA data collected by polysomnography. Participants will be able to receive high dose ato-oxy for four weeks as well as low dose ato-oxy for four weeks in random order. Participants in the study will be subjected to eligibility screening that will include an initial screening to see if non-pSG enrollment requirements are fulfilled, as well as a 1 night in-lab PSG and health-related quality of life testing for participants who qualify based on non-PSG criteria. The screening PSG night will be used as the baseline measure for apnea hypopnea index and other PSG endpoints for participants who are eligible and enroll in the study. Participants will resume for inpatient PSG and health-related quality of life assessment on the final night of dosing for both high dose ato-oxy and low-dose ato-oxy.

Source link: https://clinicaltrials.gov/ct2/show/NCT04115878

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions